Daniel Catenacci @DocCatenacci

Medical Oncologist. "Targeted therapies for targeted populations” linkedin.com/in/daniel-cate… Chicago, IL Joined June 2014

Tweets

2K
Followers

3K
Following

371
Likes

3K

Daniel Catenacci @DocCatenacci

12 months ago

@fernandbteich Yes, I would probably for ESCC, especially for higher PDL1 (like >10) although your point is quite valid.

0 0 1 60 0

View Details

Daniel Catenacci @DocCatenacci

12 months ago

#CM577 If only we could have known years ago, maybe we could’ve spared all those patients ineffective (worse than nothing?), toxic expensive therapy.

Daniel Catenacci @DocCatenacci

5 years ago

#CM577 there is no benefit (especially CPS0) in CPS low/neg tumors. 44% of pts. And this is not even by histology which would make adenocarcinoma look even worse. Why is this buried in the supplement? & Why would you give this drug for a year to people having no benefit?

6 11 27 0 2

1 5 17 3K 4

View Details

Daniel Catenacci @DocCatenacci

12 months ago

@fernandbteich First, #CM577 should be considered obsolete anyway for adenocarcinoma due to #ESOPEC & #MATTERHORN. But yes, OS in CM577 would be even less impressive if the control arm actually got SOC antiPD1 in first line at recurrence when appropriate (ie PDL1+ and or MSI-H).

1 0 3 99 0

View Details

Daniel Catenacci @DocCatenacci

12 months ago

@fernandbteich Oh sorry I misunderstood your comment ‘drawing the line’. Yes, rather than requiring proof before doing certain treatments, some do it until it is disproved 10 times before it is stopped, maybe.

1 0 1 58 0

View Details

Daniel Catenacci @DocCatenacci

12 months ago

@PiessenG @MagnusNsurgonc Those numbers are DFS. If you’re just looking at the numbers, would you rather live (OS) 39.2 months or 52.8 months? 🤔👇🏼

0 0 0 40 0

View Details

Daniel Catenacci @DocCatenacci

5 years ago

Joao Fogacci @FogacciJoao

5 years ago

@pashtoonkasi @NEJM @OncoAlert @sitcancer @DocCatenacci @GIcancerDoc @agrothey @EileenMOReilly @AnwaarSaeed3 @marklewismd @ILSONDavid @HH_Oncodr @KlempnerSam 💡Some OncGI fellows have pointed: ➡️Supplementary Appendix: 📌 CPS PDL1 =/> 5 (371 pt): 29.4 ❌ 10.2 m 📌 CPS PDL1 <5 ( 295 pt) : 16.3 ❌ 11.1 m

7 7 32 0 2

6 11 27 0 2

View Details

Daniel Catenacci @DocCatenacci

12 months ago

@fernandbteich Where to draw the line to what is called HER2+ for trastuzumab? Why is the FISH ratio of 2 used, not 1.9 or 2.5? Or Claudin18.2+ for zolbetuximab why is 2+ in 75% of cells used? They are not perfect either, but it is done, which is better than giving those drugs to everybody.

1 0 0 118 0

View Details

Daniel Catenacci @DocCatenacci

12 months ago

#MATTERHORN Phase III FLOT + durvalumab or placebo #dejavu #samsara

Daniel Catenacci @DocCatenacci

12 months ago

@LizzySmyth1 HR 0.78 NS per the presentation but not in the paper (rather HR 0.99 <12m HR 0.67) >12m) Where have we seen this tuning fork curve before? ~1/3 pts no diff. CM577 I think it’s a good idea to see the results by PDL1 1, 5, 10: will likely show same thing as all previous studies

0 2 6 1K 4

0 4 12 882 4

View Details

2 years ago

Better late than never, I guess.

Lizzy Smyth @LizzySmyth1

2 years ago

📢 FDA ODAC gets it ✅️ for patients Immune checkpoint inhibitors are a PD-L1 targeted 🎯 therapy in GEA. No target, no efficacy. Let's focus on: ➡️ alternative targets (CLD 18.2, FGFR2b, MTAP...) ➡️ overcoming immune evasion (bispecifics, T-cell engagers, CAR-T..)

0 7 24 4K 4

1 1 10 2K 0

View Details

Daniel Catenacci @DocCatenacci

2 years ago

@TimTheSurgeon Please share what you heard.

2 0 1 476 0

View Details

Daniel Catenacci @DocCatenacci

2 years ago

@aysegulilhanmut MSS. For MSI-H, for me, it remains to be seen if it should be IO alone or IO+chemo.

1 0 1 40 0

View Details

Daniel Catenacci @DocCatenacci

2 years ago

#TOPGEAR @ESMO2024 - periop chemo +/- RT for #GEA - no benefit adding RT - now 6 Phase 3 studies w/o CRT benefit vs or added to neoADJ/ADJ tx for GEA: - CRITICS, ARTIST1, ARTIST2, neoAEGIS, ESOPEC, TOPGEAR - SOC is periop #FLOT for all GEA

Lizzy Smyth @LizzySmyth1

2 years ago

Time to move away from radiotherapy in operable GEA #ESMO24 TOPGEAR ➡️ no survival benefit when RT added to periop chemo TOPGEAR + ESOPEC : both great trials with a definitive answer = no more RT ✅Great drugs in development - let's focus on systemic Rx for cure @myESMO

5 41 120 15K 20

2 17 52 11K 23

View Details

Krishan Jethwa @KrishanJethwa

2 years ago

🚨PRODIGE23🚨 Long term results now published! T3-4 rectal adenocarcinoma Randomized: CRT➡️🔪➡️FOLFOX mFOLFIRINOX ➡️ CRT➡️🔪➡️FOLFOX ✅✅✅Improved OS!!! Looking forward to JANUS clarifying if TNT with FOLFIRINOX vs. FOLFOX improves cCR and/or DFS/OS pubmed.ncbi.nlm.nih.gov/38986769/

2 97 216 19K 79

View Details

Daniel Catenacci @DocCatenacci

2 years ago

Already Approved in Japan 3/26/24. Different manufacturing sites for the two countries hopefully?? astellas.com/en/system/file…

0 0 4 308 0

View Details

Daniel Catenacci @DocCatenacci

2 years ago

#SPOTLIGHT #GLOW #Zolbetuximab #Vyloy "Zolbetuximab BLA resubmitted 5/9/2024, after CRL issued on 1/4/2024 by FDA due to 3rd-party manufacturer deficiencies seen during the pre-license inspection of the facility." Target Action Date: 11/9/2024 newsroom.astellas.us/2024-05-30-U-S….